CYBN | Cybin Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	9.11 - 9.67
52 Week Range	6.50 - 19.84
Beta	1.25
Implied Volatility	626.25%
IV Rank	44.68%
Day's Volume	387,917
Average Volume	350,353
Shares Outstanding	19,991,900
Market Cap	192,122,159
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-09-13

Valuation
Profitability
Growth
Health
P/E Ratio	-1.61
Forward P/E Ratio	N/A
EPS	-5.97
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	50
Country	Canada
Website	CYBN

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

CYBN's peers: ATAI, MNMD, SEEL, GHRS, AWKNF, FBIO, BPTH, VCNX, ELYM, OPT, MOLN, EWTX, ITOS, IMMX, CNSP, VECT, ZURA, ZVSA

*Chart delayed

Analyzing fundamentals for CYBN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see CYBN Fundamentals page.

Watching at CYBN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CYBN Technicals page.